There’s a famous quote by Friedrich Nietzsche that says “That which does not kill us makes us stronger.” I have follicular ...

Follicular lymphoma is the most common type, but others include marginal zone, cutaneous T-cell and lymphoplasmacytic ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...

The remaining patients had the following: marginal zone lymphoma (10.9%); follicular lymphoma (2.5%); Burkitt lymphoma (2.2%) ...

Even if care teams have all of your information on their end, advocating for yourself is still necessary during cancer ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.